Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Ezetimibe added to statin therapy after acute coronary syndromes
IMPROVE-IT Investigators
Clinical Departments
Cardiology
Internal Medicine
Medicine Dean & Assoc. Deans
Harvard University
Duke University
University of Montreal
Vivantes Neukölln Medical Center
Carmel Medical Center
Canisius Wilhelmina Hospital
Leiden University
University of Pavia
Cardinal Stefan Wyszynski Institute of Cardiology
Merck
Research output
:
Contribution to journal
›
Article
›
peer-review
3527
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ezetimibe added to statin therapy after acute coronary syndromes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Absolute Risk Difference
14%
Acute Coronary Syndrome
100%
Adverse Effects
14%
Cardiovascular Events
14%
Cardiovascular Mortality
14%
Cardiovascular Outcomes
14%
Cardiovascular Risk
14%
Confidence Interval
14%
Coronary Revascularization
14%
Double-blind Randomized Trial
14%
Event Rate
14%
Ezetimibe
100%
Gallbladder
14%
Hazard Ratio
14%
Intestinal Cholesterol Absorption
14%
Kaplan-Meier
14%
Lipid-lowering Therapy
28%
Low-density Lipoprotein Cholesterol (LDL-C)
14%
Low-density Lipoprotein Cholesterol Level
57%
Median Time
14%
Monotherapy
42%
Non-statins
14%
Nonfatal Myocardial Infarction
14%
Nonfatal Stroke
14%
Placebo
14%
Rehospitalization
14%
Simvastatin
100%
Stable Angina
14%
Statin Therapy
100%
Time-weighted Average
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
100%
Adverse Event
14%
Ezetimibe
100%
Heart Infarction
14%
Low Density Lipoprotein Cholesterol
71%
Malignant Neoplasm
14%
Monotherapy
42%
Placebo
14%
Simvastatin
100%
Statin (Protein)
100%
Unstable Angina Pectoris
14%